Navigation Links
IMPAKT -- Translational research breast cancer conference
Date:4/11/2013

n as possible:
  • Biomarker data including
    • Predicting risk for late metastasis: the PMA50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer: a study on 1,478 patients from the ABCSG-8 trial (53 O)
    • Prognostic and predictive value of IHC4 and ERB1 in the integroup exemestane study (IES) on behalf of the pathies investigators (55 O)
    • Comparison of five different scores for the prediction of late recurrence for oestrogen receptor positive breast cancer (54 O)
    • Predictive value of AKT/mTOR pathway immunohistochemical (IHC) biomarkers for response to pre-operative trastuzumab vs. trastuzumab + everolimus in patients with early breast cancer: UNICANCER RADHER trial results (56 O)
  • Heterogeneity of breast cancer including
    • Contribution of analytical, pre-analytical and intra-tumoral heterogeneity to variance in gene expression measurements from human breast cancers (40 O)
    • Heterogeneity of genomic signatures in breast cancer core biopsy (41 O)
    • Assessment of Genetic Alterations in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer From the BOLERO-2 Trial by Next-Generation Sequencing (42 O)

Press conference

Thursday, 2 May 2013, 10:45-11:45 (CEST)

Hosts: Martine Piccart, Jules Bordet Institute, Head of Chemotherapy Unit, Brussels, Belgium, IMPAKT Co-Founder Peter Dubsky, Vienna General Hospital (AKH) - Medizinische Universitt Wien, Vienna, Austria, IMPAKT2013 Scientific Chair Andrew Tutt, King's College London Guy's Hospital, London, United Kingdom, IMPAKT2013 Executive Chair

BIG and ESMO welcome media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the Media Policy < '/>"/>

Contact: ESMO PRess Office
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Fourth IMPAKT Breast Cancer Conference
2. Hot topics in translational bone research at IOF-ESCEO 3rd Pre-Clinical Symposium
3. Autism Speaks and SAGE® Labs develop rat models for translational autism research
4. Elsevier launches new open access journal: Applied and Translational Genomics
5. BUSM researchers identify novel approach to study COPD and treatment efficacy
6. LSUHSC research discovers new drug target for metastatic breast cancer
7. Researchers call for marine observation network
8. Biofilms help Salmonella survive hostile conditions, Virginia Tech researchers say
9. Feinstein Institute collaborates with GSK, UPenn, MIT to research bodys electrical impulses
10. U-M researchers find new way to clear cholesterol from the blood
11. New cutting-edge cell research will lead to safer medical experiments on humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... think they have solved an interesting problem: how to ... and complete vegetable protein. What,s more, they,ve joined forces ... soy snack they,ve developed into the hands of 1.2 ... the country has decidedly vegetarian tastes, the Indian people ...
... sensor that may revolutionize how drugs and medical devices are ... the survival of two species of threatened animals. To ... frog. In the wild, the African clawed frog produces ... its skin to protect it from infection. Princeton researchers have ...
... at Yale School of Medicine have found that new ... to Type 1 Gaucher disease, a rare genetic disorder ... resulting in liver/spleen enlargement, osteoporosis, bone pain, and increased ... new findings could lead to less expensive and more ...
Cached Biology News:Illinois scientists promote soy by currying favor with Indian taste buds 2New sensor derived from frogs may help fight bacteria and save wildlife 2New sensor derived from frogs may help fight bacteria and save wildlife 3Cheaper, more effective treatment of type 1 Gaucher disease possible 2
(Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: UTHR ... MDT ) has submitted a pre-market approval application to ... use of Medtronic,s SynchroMed ® II implantable drug ... with United Therapeutics, Remodulin ® (treprostinil) Injection delivered ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Feb. 25 The International,Confocal Microscopy Working ... students, has been formed as a means ... reflective confocal microscopy (RCM) in,patient care., ... new members worldwide.,Dermatologists, dermascopists, dermatopathologists, medical students ...
... MONTVALE, N.J., Feb. 25 Barr Pharmaceuticals,Inc. ... its subsidiary, Duramed,Pharmaceuticals, Inc., has received notification ... has accepted for review its New Drug ... 0.10,mg/0.02 mg and ethinyl estradiol tablets 0.01 ...
... (OTC Bulletin Board: NILT.OB), a biopharmaceutical company focused ... announce the,appointment of Hsiao Dee Lieu, M.D., F.A.C.C. ... am delighted to welcome Dr. Lieu to Nile. ... should be immediately,beneficial to Nile and our CD-NP ...
Cached Biology Technology:International Confocal Microscopy Working Group Established to Advance Practice of Reflective Confocal Microscopy 2Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 2Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 3Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 4Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics 2Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics 3
...
... Immunogen: Synthetic peptide derived from ... rat mouse dog and orangutang occludin ... human occludin protein. Reactivity: Human ... Reactivity with rat mouse dog and ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Biology Products: